Aurora Cannabis Forms Special Committee in Response to Curaleaf's Hostile Bid
ACB sits 36% above its 52-week low of $2.56 on elevated volume (5.5× avg).
Summary
Aurora Cannabis confirmed receipt of an unsolicited takeover bid from Curaleaf at US$4.00 per share, a 45% premium to recent trading. The board is forming a special committee to evaluate the offer, which includes a US$5.00 cap below prior trading levels. This marks the first public response to the hostile approach.
Key Events · M&A and Partnerships · ACB
-
Hostile Takeover Bid Received
Curaleaf launched an unsolicited bid for all Aurora shares at US$4.00 each, consisting of 0.3463 Curaleaf shares plus US$0.75 cash, implying a 45% premium to Aurora's recent price.
-
Prior Proposals Disclosed
Aurora revealed it received letters from Curaleaf on June 23 and July 7, 2026; the July letter included financial terms but no cash/stock mix, and the current bid adds a US$5.00 cap below Aurora's December 2025 trading price.
-
Board Forms Special Committee
Aurora's board will form a special committee of independent directors to evaluate the proposal, with no decision made yet and no assurance of a transaction.
-
Strategic Assets Highlighted
Aurora emphasized its recently acquired Safari Flower Company and growing EU-GMP cultivation capacity as key strategic assets that Curaleaf finds attractive.
Analysis · ACB · Life Sciences
For the first time, Aurora Cannabis publicly acknowledged Curaleaf's unsolicited takeover bid, disclosing that prior proposals were received as early as June 23, 2026. The current offer of US$4.00 per share—comprising 0.3463 Curaleaf shares plus US$0.75 cash—includes a cap of US$5.00, which sits below Aurora's trading price in late 2025. Signaling a formal review, the board is forming a special committee to evaluate the bid. This hostile approach, combined with Aurora's recent material weaknesses and mixed financial results, puts the company in play and could trigger a bidding war or defensive measures. Given the 45% premium implied by the offer and the strategic importance of Aurora's EU-GMP assets, the news is highly market-moving.
At the time of this filing, ACB was trading at $3.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.